SS-31 and MOTS-c: Do Cellular Energy Peptides Actually Work?

If you have looked into peptides for low energy, you have met SS-31 and MOTS-c. They are sold online as "cellular energy" peptides and marketed as a way to repair tired mitochondria and lift fatigue. The pitch is scientifically literate, which is part of why it persuades.

Here is what the human evidence shows, and it is more interesting than either the marketing or a flat dismissal would suggest. SS-31, known in the medical literature as elamipretide, went through a large and rigorous trial in primary mitochondrial myopathy and missed both of its primary endpoints. It then went on to receive FDA accelerated approval in September 2025, under the brand name Forzinity, for one narrowly defined disease: Barth syndrome. MOTS-c, the other half of the pair, produced its headline results in mice and has only just entered controlled human testing, with no results reported yet.

Neither of those stories supports using these compounds as general purpose energy or longevity peptides. But "SS-31 failed" is not an accurate summary either, and the reason why is the most useful thing on this page.

One point of vocabulary first. "Cellular energy peptide" is a marketing category, not a medical classification. SS-31 and MOTS-c are both associated with mitochondria and are otherwise very different molecules doing very different jobs.

What SS-31 and MOTS-c Are Designed to Do

Mitochondria generate most of the chemical energy needed to power cellular biochemical reactions. When genetic mutations impair their ability to convert nutrients into usable energy, a condition known as primary mitochondrial myopathy can develop. This genetic disorder affects the process of oxidative phosphorylation (the primary cellular mechanism for producing energy), leaving skeletal muscles starved of power. Patients frequently experience severe exercise intolerance, chronic muscle weakness, and debilitating fatigue during everyday activities.

For decades, clinical care for mitochondrial diseases has relied primarily on supportive measures, vitamins, and symptom management. However, researchers have explored targeted peptides designed to support the inner mitochondrial membrane. Among these investigational compounds, elamipretide, sold and discussed online under its research name SS-31, has received substantial attention. By binding to cardiolipin, a specialized lipid found exclusively in the inner mitochondrial membrane, elamipretide was designed to stabilize membrane structure, reduce oxidative stress, and restore energetic efficiency.

Despite high expectations from early preclinical models, translating targeted mitochondrial therapies into measurable functional gains in broad human cohorts remains a formidable challenge.

The MMPOWER-3 Trial: Evaluating Elamipretide Efficacy

The phase 3 MMPOWER-3 randomized clinical trial, published in the journal Neurology, evaluated the efficacy and safety of daily subcutaneous elamipretide in individuals with genetically confirmed primary mitochondrial myopathy.

The trial cohort had a mean age of 45.6 years, with 64% female participants and 94% identifying as White. Genetic testing revealed that 74% of participants had mutations in their mitochondrial DNA, while the remaining 26% had defects in nuclear DNA that affect mitochondrial function. At the start of the study, the most bothersome symptom reported by patients was severe tiredness during physical activities, recorded in 28.9% of participants.

To gauge clinical efficacy, investigators established two co-primary endpoints:

• Change from baseline to week 24 in distance walked during the standardized 6-minute walk test.
• Change in total fatigue scores measured by the Primary Mitochondrial Myopathy Symptom Assessment.

Secondary outcomes tracked quality of life using the Neuro-QoL Fatigue Short-Form and clinician and patient global impressions of symptom severity.

Clinical Trial Outcomes and Primary Endpoints

At baseline, participants walked an average distance of 336.7 meters during the 6-minute walk test, with a mean Primary Mitochondrial Myopathy Symptom Assessment fatigue score of 10.6. After 24 weeks of daily treatment, the trial did not meet its primary efficacy endpoints:

• 6-Minute Walk Test: The difference in least squares mean change between the elamipretide and placebo groups was -3.2 meters (95% confidence interval, -18.7 to 12.3 meters; p = 0.69).
• Fatigue Score: The difference in total fatigue score change between groups was -0.07 points (95% confidence interval, -0.10 to 0.26; p = 0.37).
• Secondary Metrics: Neuro-QoL fatigue scores and clinician global impression ratings similarly demonstrated no statistically significant differences between elamipretide and placebo.

The trial authors state that these findings provide Class I evidence, the highest quality rating in the neurology evidence grading system, that a 24-week course of subcutaneous elamipretide does not improve the 6-minute walk test or fatigue in patients with primary mitochondrial myopathy. This is not an inconclusive or underpowered result. It is a well-designed study reporting that elamipretide did not improve these two prespecified endpoints in the overall population studied. That is a narrower statement than "the drug does not work", and the difference turns out to matter.

A genotype-specific analysis of the same trial makes the point concretely. The prespecified subgroup whose disease came from nuclear DNA variants did show improvement on the 6-minute walk test, while the much larger mitochondrial DNA group showed no difference from placebo. A post hoc cohort with defects in the mtDNA replisome walked 25.2 metres further than baseline against 2.0 metres on placebo, a difference that only trended towards significance (p = 0.06). None of this overturns the headline result, and a subgroup finding is a hypothesis rather than a conclusion. It does suggest the negative result may reflect a mixed population rather than an inert drug.

Tolerability and Adverse Events

Although elamipretide did not demonstrate functional superiority over placebo, the trial confirmed that the peptide was generally well tolerated. Most reported adverse events were mild to moderate in severity, predominantly consisting of localized injection-site reactions such as erythema, swelling, or minor discomfort.

Differential Responses: Insights From Barth Syndrome Research

The neutral functional findings in primary mitochondrial myopathy stand in contrast to data gathered in more genetically homogeneous disorders. In a separate long-term study published in Genetics in Medicine, researchers evaluated elamipretide in individuals with Barth syndrome during the TAZPOWER open-label extension trial. Barth syndrome is an ultra-rare genetic disorder caused by mutations in the TAZ gene, which directly alters cardiolipin remodeling.

Investigators tracked changes in the 6-minute walk test, Barth Syndrome Symptom Assessment fatigue scores, muscle strength, echocardiographic parameters, and cardiolipin-to-monolysocardiolipin ratios. Eight of the 10 enrolled patients completed the full 168-week evaluation.

Unlike the heterogeneous population in MMPOWER-3, patients in the open-label Barth syndrome extension demonstrated sustained tolerability and improvements in functional walk metrics and strength measures over multi-year follow-up.

On 19 September 2025 the FDA granted accelerated approval to elamipretide, marketed as Forzinity, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms. It is the first approved treatment for Barth syndrome and the first mitochondria-targeted therapy of its kind to reach approval.

The reasoning behind that approval is worth understanding, because it is unusual. The approval rests on improvement in knee extensor muscle strength, an intermediate endpoint considered reasonably likely to predict clinical benefit rather than a demonstration of benefit itself. That strength improvement was not seen during the randomised portion of the Barth trial. It emerged during the open-label extension, in a study that randomised 12 patients in total. Accelerated approval is a conditional pathway used where a disease is serious, rare and untreated, and it obliges the sponsor to confirm the benefit afterwards.

So the honest summary of elamipretide is neither "it works" nor "it failed". It is that a drug can miss its endpoints across a broad biological category and still earn approval for one narrowly defined disease where its molecular target happens to be the actual cause. Barth syndrome is caused by variants in the TAZ gene that directly disrupt cardiolipin remodelling, which is precisely what this molecule binds. That is a far more useful lesson than either slogan, and it is the opposite of evidence that the compound raises energy in a healthy person.

The Broader Spectrum of Mitochondrial Signaling Peptides

While elamipretide directly targets inner membrane lipids, other research explores how mitochondria act as active signaling hubs. In a landmark study published in Cell Metabolism, researchers identified a mitochondrial-derived peptide called MOTS-c and its role in metabolic homeostasis. Encoded within a short open reading frame of the mitochondrial 12S ribosomal RNA, MOTS-c acts as a cellular signaling hormone.

In preclinical mouse models, MOTS-c targeted skeletal muscle tissue, inhibiting the folate cycle and tethered purine synthesis to stimulate adenosine monophosphate-activated protein kinase (AMPK, an enzyme that regulates cellular energy balance). This mechanism improved systemic insulin sensitivity, prevented age-associated insulin resistance, and reduced diet-induced obesity in experimental animals.

Until recently that was the whole story, and it was entirely a mouse story. That is now changing. A randomised, double-blind, placebo-controlled phase 2 trial (NCT07505745) began recruiting in February 2026, giving subcutaneous MOTS-c to 120 adults with prediabetes and overweight or obesity, with insulin sensitivity measured by the Matsuda index as its primary efficacy outcome and treatment-emergent adverse events as a co-primary safety outcome. It is recruiting in Shenzhen, China. No results have been posted.

The precise position, then, is not that MOTS-c has never been given to humans. It is that no results from a controlled human trial of administered MOTS-c are available yet. Anyone selling it today is selling ahead of the evidence that is currently being gathered.

What would change our view of MOTS-c

The next meaningful evidence is not another mouse experiment. It is controlled human data showing whether administered MOTS-c changes insulin sensitivity, metabolic markers, body composition or safety outcomes against placebo. If that trial reports a real effect on insulin sensitivity, MOTS-c becomes a serious metabolic candidate worth following closely. If it does not, the mouse findings will join a long list of mechanisms that never survived contact with human physiology. Either way the answer will come from that trial and others like it, not from testimonials.

Scientific Analysis: Why Broad Mitochondrial Trials Face Challenges

Comparing the results of MMPOWER-3 with TAZPOWER and preclinical peptide discoveries yields critical insights for translational medicine:

• Genetic Heterogeneity: Primary mitochondrial myopathies represent an umbrella classification encompassing dozens of distinct mitochondrial DNA and nuclear DNA mutations. A therapeutic agent targeting inner membrane stabilization may not overcome profound enzymatic deficits in the respiratory chain complexes across mixed cohorts.
• Trial Duration and Tissue Dynamics: One possibility is that a 24-week window was too short to produce measurable functional change in chronically affected muscle, given long-standing remodelling, fibrosis and motor unit loss. This is a hypothesis about why the trial read out as it did, and the trial itself does not establish it.
• Endpoint Sensitivity: While the 6-minute walk test is a standard regulatory measure, it is influenced by multiple systemic variables, potentially obscuring subtle biochemical changes occurring within specific muscle fibers.

Online health forums and consumer wellness channels frequently discuss peptide therapies as universal boosters of cellular vitality. The MMPOWER-3 data serves as an essential scientific reality check. Molecular mechanisms observed in laboratory models do not automatically yield tangible physical improvements in human clinical trials without precise disease targeting.

Study Limitations

Several limitations should be considered when interpreting these trial results:

• Cohort Diversity: The MMPOWER-3 study population was 94% White, which limits the generalizability of the findings across more ethnically diverse genetic backgrounds.
• Variable Pathogenicity: The trial included participants with both mitochondrial DNA mutations (74%) and nuclear DNA defects (26%), introducing substantial clinical variability into the primary analysis.
• Sample Size Constraints in Extension Trials: The supporting TAZPOWER extension trial in Barth syndrome involved a very small cohort (10 participants) and utilized an open-label design, which increases the risk of observational bias.
• Translational Gap: Research regarding mitochondrial-derived signaling peptides like MOTS-c remains largely confined to rodent models and cell cultures, meaning metabolic effects in human health cannot yet be assumed.

What You Are Actually Buying

Neither compound is an approved medicine for raising energy in healthy people, but they now sit in different regulatory places and the difference matters.

Elamipretide exists as an approved pharmaceutical, Forzinity, prescribed for Barth syndrome and manufactured to pharmaceutical standards. That is a completely different thing from a vial sold online under the research name SS-31. An approval for an ultra-rare genetic cardiolipin disorder is not an endorsement for fatigue, ageing or athletic performance, and the approved product is not what a consumer receives from a peptide seller.

MOTS-c remains investigational. Material sold outside a clinical trial is not equivalent to the pharmaceutical-grade compound being administered under supervision in the phase 2 trial described above.

Both are sold online as research chemicals, a category that exists precisely because it sits outside medicines regulation. No regulator verifies the identity, purity, sterility or quantity of what arrives in the vial, and there is no recall mechanism when a batch is wrong. A buyer cannot confirm that the contents match the label. That matters for reading everything above: the trial evidence was generated with pharmaceutical-grade compound under medical supervision, and it does not describe what a consumer receives from an online seller.

Practical Takeaways

If you are tired enough to be researching injectable peptides, the more useful question is what is causing the tiredness.

• The largest human test was negative for fatigue. SS-31 did not beat placebo on fatigue or walking distance in people with genetically confirmed mitochondrial disease, the group with the most room to improve. No trial has tested it in healthy tired adults, so using it for ordinary tiredness rests on inference from a negative result rather than on evidence of benefit.
• Its approval is not a general endorsement. Elamipretide is approved for Barth syndrome, an ultra-rare disorder that directly disrupts the exact molecule the drug binds, on an intermediate strength endpoint under a conditional pathway. Nothing about that approval speaks to ordinary fatigue.
• MOTS-c has no controlled human results yet. Its metabolic findings are from mice, and the first controlled human trial is recruiting now. That is a reason for scientific interest, not a reason to inject it ahead of the answer.
• Common causes of fatigue are worth excluding first. Disrupted sleep, iron deficiency, thyroid dysfunction, sleep apnoea, depression, and side effects of existing medication are all common, all detectable with ordinary testing, and all treatable. A doctor can rule these out in a way no peptide protocol can.